case_images: PMC10510339_01
case_images: (a) Extensive ulceration 4 months after Mohs surgery on the medial aspect of the right ankle. The patient was currently taking pazopanib. The ulceration showed necrotic debris, exudate, steep edges, areas of undermining, and necrotic edges. (b) Healing ulceration with evidence of closure and good granulation tissue. Pazopanib had been discontinued for 2 months.
case_images: 10.1177_2050313X231200967-fig1.jpg
case_images: PMC10510339_01_10.1177_2050313X231200967-fig1.jpg
case_images: fig1-2050313X231200967
case_images: Despite all these modalities, over a 4-month period, his wound expressed progressive undermining, nonremovable necrotic debris, and necrotic edges (Figure 1a). Soon after the discontinuation, the patient experienced rapid and dramatic closing of his ulceration over 2 months (Figure 1b). The patient was restarted on pazopanib due to tumor progression (6 months after discontinuation of initial pazopanib), and his wound site on the right LE began demonstrating increasing ulceration with some necrosis and extensive exudate over 2 months (Figure 2b and Table 1).
case_images: (a) Almost complete healing of the ulceration 3 months after discontinuation of pazopanib. (b) Recurrence of a deep ulceration 8 weeks after restarting pazopanib.
case_images: 10.1177_2050313X231200967-fig2.jpg
case_images: PMC10510339_01_10.1177_2050313X231200967-fig2.jpg
case_images: fig2-2050313X231200967
case_images: After discharge from the hospital, the wound on the LE showed almost complete closure with buds of granulation tissue (Figure 2a). The patient was restarted on pazopanib due to tumor progression (6 months after discontinuation of initial pazopanib), and his wound site on the right LE began demonstrating increasing ulceration with some necrosis and extensive exudate over 2 months (Figure 2b and Table 1).